Apeloa

Apeloa Pharmaceutical Co., Ltd. (普洛药业股份有限公司) is a China-based pharmaceutical manufacturing and services company founded in 1989 and headquartered in Hengdian, Dongyang, Zhejiang. It is the pharmaceutical industry platform of the well-known private enterprise Hengdian Group and is listed on the main board of the Shenzhen Stock Exchange under the ticker 000739. The company describes itself as a leading technology-driven pharmaceutical manufacturing service enterprise, with a registered capital of RMB 1.178 billion and more than 7,000 employees. Apeloa operates across four main business segments: CDMO (contract development and manufacturing for innovative drugs), APIs and intermediates, finished drugs, and beauty and cosmetic ingredients. Its CDMO business offers global, one-stop services to innovative pharmaceutical companies, supported by R&D and manufacturing capabilities in China and overseas. In APIs and intermediates, Apeloa is a leading domestic producer and exporter, active in both chemical synthesis and biological fermentation, supplying high-quality APIs to pharmaceutical companies worldwide. Its finished-drug business follows a multi-product strategy, leveraging the company's API-drug integration and high-barrier formulation technology platforms. The beauty and cosmetic ingredients segment focuses on R&D, production, and sales of ingredients such as UV filters, cosmetic peptides, and synthetic biology products, serving leading global cosmetic ingredient companies. According to its official website, Apeloa ranks 43rd among China's pharmaceutical industrial enterprises, second in China in chemical API exports, and among the top five Chinese small-molecule CDMO companies. It has been listed among the "Top 100 Chinese Listed Companies with the Most Growth Potential" and designated as a leading enterprise in Zhejiang Province's biopharmaceutical industry and a Zhejiang "Eagle Enterprise." The company has R&D personnel numbering more than 1,300 and invests over 5% of revenue annually in R&D. It has established technology platforms including flow chemistry, crystal and powder engineering, synthetic biology and enzyme catalysis, and peptides, and is advancing continuous, automated, digital, and intelligent pharmaceutical manufacturing. Apeloa's global footprint includes headquarters and API technology platforms in Hengdian, Zhejiang; a CDMO R&D service platform in Hangzhou; global business and trade services in Hangzhou; a CDMO R&D service platform in Shanghai Pudong; and business offices in Tokyo, Frankfurt, and a CDMO R&D service platform in Boston. Its manufacturing bases are located in Dongyang (Zhejiang), Weifang (Shandong), Dongzhi (Anhui), and Quzhou (Zhejiang). The company's quality system, in place since 2007, has seen major API plants pass official audits by China's NMPA, the U.S. FDA, the EU EMEA, and Japan's PMDA. Its stated mission is "Technology creates, serves health" and its vision is to become a globally leading technology-driven pharmaceutical manufacturing service enterprise.

Apeloa Pharmaceutical Co., Ltd. was founded in 1989 and is the pharmaceutical industry platform of Hengdian Group, a well-known Chinese private enterprise. The company is headquartered in Hengdian, Dongyang, Zhejiang, and is listed on the main board of the Shenzhen Stock Exchange under stock code 000739. Over the decades, Apeloa has grown from its roots in pharmaceutical manufacturing into a diversified pharmaceutical company with four main business segments: CDMO, APIs and intermediates, finished drugs, and beauty and cosmetic ingredients. In its API and intermediate business, Apeloa has become a leading domestic producer and exporter, active in both chemical synthesis and biological fermentation. The company supplies APIs across major therapeutic areas including anti-infectives, nervous system drugs, cardiovascular drugs, blood system drugs, and respiratory system drugs. Its quality system has been in place since 2007, and major API plants have passed official audits by China's NMPA, the U.S. FDA, the EU EMEA, and Japan's PMDA. This regulatory track record has supported its position as a top Chinese API exporter. The company has also built a significant CDMO business, providing global, one-stop services to innovative pharmaceutical companies. It has established R&D and manufacturing platforms in Hengdian, Hangzhou, Shanghai, and Boston, and business offices in Tokyo and Frankfurt. Its CDMO services are supported by technology platforms including flow chemistry, crystal and powder engineering, synthetic biology and enzyme catalysis, peptides, high-potency compounds, conjugation, and oligonucleotide synthesis. In finished drugs, Apeloa follows a multi-product strategy, leveraging its API-drug integration and high-barrier formulation technology platforms. It has established well-known domestic brands such as "Baishixin" and "Tianliwei," and its first high-end controlled-release formulation has entered the U.S. market. The company has also expanded into beauty and cosmetic ingredients, focusing on UV filters, cosmetic peptides, moisturizing, and whitening ingredients, serving leading global cosmetic ingredient companies. Apeloa invests over 5% of its revenue annually in R&D and has more than 1,300 R&D personnel. It has established a Science and Technology Advisory Committee and collaborates with Shanghai Jiao Tong University, Shanghai Institute of Technology, and Zhejiang University of Technology on biology, chemistry, and engineering technology platforms. The company is advancing continuous, automated, digital, and intelligent pharmaceutical manufacturing. Its stated mission is "Technology creates, serves health," and its vision is to become a globally leading technology-driven pharmaceutical manufacturing service enterprise.

• 2007

  Company quality system begins; major API plants subsequently pass NMPA, FDA, EMEA, and PMDA audits.

• 1989

  Apeloa Pharmaceutical Co., Ltd. is founded.

• Listed on the Shenzhen Stock Exchange Main Board under stock code 000739.

• First high-end controlled-release formulation enters the U.S. market.

• Establishes CDMO R&D service platform in Boston, USA.

• Establishes business offices in Tokyo, Japan and Frankfurt, Germany.

Pharmaceutical Contract Development and Manufacturing Organization (CDMO)

• Anti-infective APIs

  Cefixime

• Anti-infective APIs

  Cefdinir

• Anti-infective APIs

  Ofloxacin

• Anti-infective APIs

  Levofloxacin Hemihydrate

• Anti-infective APIs

  Oseltamivir Phosphate

• Nervous system APIs

  Bupropion HCl

• Nervous system APIs

  Levetiracetam

• Nervous system APIs

  Quetiapine Fumarate

• Cosmetic peptides

  Glutathione

• Cosmetic peptides

  Acetyl Hexapeptide-8

• Synthetic biology-derived ingredients

  Nootkatone

• Synthetic biology-derived ingredients

  L-Ergothioneine

• 2009

  Subsidiary Illegally Dumps Hazardous Waste Across Provinces in Bozhou, Anhui

  Zhejiang Puluo Debang Pharmaceutical, affiliated with Apeloa Pharmaceutical, entrusted hazardous waste to unqualified persons for disposal; 1,047 barrels of hazardous waste were illegally dumped across provinces in Guoyang and Lixin, Bozhou, Anhui. The Ministry of Environmental Protection notified the event; Zhejiang environmental authorities fined the company 250,000 yuan; the company paid 2.2 million yuan in pollution damages and disposal costs; responsible persons were sentenced for the crime of major environmental pollution accident. It became a typical cross-provincial dumping case notified by the Ministry of Environmental Protection.

  Source

Read more

1. 1普洛药业股份有限公司官网首页apeloa.com
2. 2普洛药业股份有限公司-关于我们apeloa.com
3. 3普洛药业股份有限公司-原料药及中间体apeloa.com
4. 4普洛药业-医美及化妆品原料apeloa.com
5. 5Subsidiary Illegally Dumps Hazardous Waste Across Provinces in Bozhou, Anhuimee.gov.cn
6. 6Subsidiary Illegally Dumps Hazardous Waste Across Provinces in Bozhou, Anhuichina.caixin.com